Compare TT & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TT | BMY |
|---|---|---|
| Founded | 1885 | 1887 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.5B | 113.5B |
| IPO Year | 2009 | 2006 |
| Metric | TT | BMY |
|---|---|---|
| Price | $455.68 | $61.35 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 26 | 28 |
| Target Price | ★ $529.12 | $65.25 |
| AVG Volume (30 Days) | 1.0M | ★ 11.9M |
| Earning Date | 10-29-2026 | 10-29-2026 |
| Dividend Yield | 0.94% | ★ 4.10% |
| EPS Growth | 15.48 | ★ 178.46 |
| EPS | ★ 6.78 | 2.93 |
| Revenue | $14,782,000,000.00 | ★ $48,194,000,000.00 |
| Revenue This Year | $11.47 | $3.54 |
| Revenue Next Year | $9.82 | N/A |
| P/E Ratio | $65.91 | ★ $21.05 |
| Revenue Growth | ★ 5.58 | N/A |
| 52 Week Low | $348.06 | $42.52 |
| 52 Week High | $505.87 | $68.64 |
| Indicator | TT | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 48.95 | 50.09 |
| Support Level | $438.55 | $59.91 |
| Resistance Level | $474.26 | $62.77 |
| Average True Range (ATR) | 13.13 | 1.81 |
| MACD | -2.38 | 0.45 |
| Stochastic Oscillator | 42.14 | 68.28 |
Trane Technologies manufactures and services commercial and residential HVAC systems and transportation refrigeration solutions under its prominent Trane, American Standard, and Thermo King brands. The company generates approximately 70% of sales from equipment and 30% from parts and services. While the firm is domiciled in Ireland, North America accounts for approximately 80% of its revenue, with 13% from EMEA and 7% Asia-Pacific. The company was formed in 2020 when its former parent, Ingersoll Rand, merged with Gardner Denver in a tax-advantaged reverse Morris trust transaction.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.